title: Increase of ceftazidime- and fluoroquinolone-resistant Klebsiella pneumoniae and imipenem-resistant Acinetobacter spp. in Korea: analysis of KONSAR study data from 2005 and 2007.
abstract: OBJECTIVE
  Antimicrobial resistance monitoring could be a useful source of information for treating and controlling nosocomial infections. We analyzed antimicrobial resistance data generated by Korean Hospitals and by a commercial laboratory in 2005 and 2007.
  
  
  METHODS
  Susceptibility data for 2005 and 2007 were collected from 37 and 41 hospitals, respectively, and from one commercial laboratory. Intermediate susceptibility was not included in the calculation of resistance rates.
  
  
  RESULTS
  Methicillin-resistant Staphylococcus aureus (MRSA) (64%), third-generation cephalosporin-resistant Klebsiella pneumoniae (29%), fluoroquinolone-resistant Escherichia coli (27%), Pseudomonas aeruginosa (33%), and Acinetobacter spp. (48%), and amikacin-resistant P. aeruginosa (19%) and Acinetobacter spp. (37%) were prevalent in hospitals in 2007. A gradual increase of vancomycin-resistant Enterococcus faecium and imipenem-resistant Acinetobacter spp. was observed. Higher incidences of thirdgeneration cephalosporin-resistant E. coli and K. pneumoniae and imipenemresistant P. aeruginosa were found in the commercial laboratory than in the hospitals.
  
  
  CONCLUSIONS
  Methicillin-resistant S. aureus, third-generation cephalosporin- resistant K. pneumoniae, and fluoroquinolone-resistant E. coli, P. aeruginosa and Acinetobacter spp. remain prevalent in Korea, while the incidence of vancomycin-resistant E. faecium and imipenem-resistant Acinetobacter spp. has increased gradually. The higher prevalences of third-generation cephalosporinresistant E. coli and K. pneumoniae, and imipenem-resistant P. aeruginosa in the commercial laboratory are a new concern.
authors.affiliation: Department of Laboratory Medicine, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea.
authors.forename: Kyungwon
authors.initials: K
authors.lastname: Lee
authors.forename: Mi Ae
authors.initials: MA
authors.lastname: Lee
authors.forename: Chae Hoon
authors.initials: CH
authors.lastname: Lee
authors.forename: Jongwook
authors.initials: J
authors.lastname: Lee
authors.forename: Kyoung Ho
authors.initials: KH
authors.lastname: Roh
authors.forename: Sunjoo
authors.initials: S
authors.lastname: Kim
authors.forename: Jin Ju
authors.initials: JJ
authors.lastname: Kim
authors.forename: Eunmi
authors.initials: E
authors.lastname: Koh
authors.forename: Dongeun
authors.initials: D
authors.lastname: Yong
authors.forename: Yunsop
authors.initials: Y
authors.lastname: Chong
mesh_terms: D000150:Acinetobacter / Q000378:metabolism*; D001424:Bacterial Infections / Q000188:drug therapy / Q000453:epidemiology*; D002442:Ceftazidime / Q000494:pharmacology*; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology*; D024881:Drug Resistance, Bacterial; D004926:Escherichia coli / Q000378:metabolism; D024841:Fluoroquinolones / Q000494:pharmacology*; D006801:Humans; D015378:Imipenem / Q000494:pharmacology*; D007710:Klebsiella Infections / Q000188:drug therapy*; D007711:Klebsiella pneumoniae / Q000378:metabolism*; D055624:Methicillin-Resistant Staphylococcus aureus / Q000378:metabolism; D011550:Pseudomonas aeruginosa / Q000378:metabolism; D056910:Republic of Korea; D014640:Vancomycin / Q000494:pharmacology
chemical_list: D024841:Fluoroquinolones; D014640:Vancomycin; D015378:Imipenem; D002442:Ceftazidime